Skip to main content

Table 2 Genotype and survival

From: Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

 

Progression-free survival

Overall Survival

SNP and Genotype

Median (months)

HR

p

Median (months)

HR

p

XRCC1:rs25487

      

   AA or AG

31.5

1.4

0.41

23.7

0.86

0.66

   GG

NR (>38)

  

49.3

  

XRCC2:rs6464628

      

   GG or GA

22.9

1.6

0.24

53.5

1.3

0.52

   AA

NR (>31.5)

  

46.7

  

ERCC1:rs3212986

      

   GT or TT

37.9

1.1

0.78

46.7

0.96

0.90

   GG

NR (>31.5)

  

35.0

  

XPD:rs13181

      

   GG or GT

46.5

0.63

0.25

46.7

0.67

0.27

   TT

16.0

  

21.0

  

XPD:rs1799793

      

   AA or AG

NR (>40)

0.80

0.57

NR (>40)

0.59

0.14

   GG

31.4

  

21.0

  
  1. HR, hazard ratio; NR, not reached; SNP, single nucleotide polymorphism.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us